CAS No.
[1009119-64-5(Unlabeled)]
Therapeutic Uses
Antiretroviral / Anti-HIV
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester -13C2D6
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Daclatasvir-13C2,d6 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Daclatasvir-13C2,d6 usage and description
Daclatasvir 13C2D6 is a potent antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. This drug is a deuterated form of daclatasvir, which is a direct-acting antiviral drug that inhibits the non-structural protein 5A (NS5A) of HCV. It is manufactured by Bristol-Myers Squibb under the brand name Daklinza.
Daclatasvir 13C2D6 is available in tablet form and is administered orally. The recommended dose is 60mg once daily for 12 weeks in combination with other antiviral medications such as sofosbuvir or ribavirin. It is important to note that daclatasvir 13C2D6 should not be used as monotherapy as it may lead to the development of drug-resistant strains of HCV.
Chemically, daclatasvir 13C2D6 is a deuterated form of daclatasvir, which means that some of the hydrogen atoms in the drug molecule have been replaced with deuterium atoms. This modification does not alter the drug's mechanism of action or efficacy but increases its half-life and reduces its metabolism. This results in higher plasma concentrations, allowing for greater antiviral activity and reduced dosing frequency.
In conclusion, daclatasvir 13C2D6 is a highly effective medication for the treatment of chronic HCV infection. Its deuterated form provides advantages in terms of pharmacokinetics and dosing frequency. However, it should only be used in combination with other antiviral medications and under the supervision of a healthcare professional.
